<DOC>
	<DOCNO>NCT01737138</DOCNO>
	<brief_summary>To study whether renal sympathetic denervation ( RSD ) safe effective patient chronic kidney disease resistant hypertension</brief_summary>
	<brief_title>Renal Sympathetic Denervation Patients With Chronic Kidney Disease Resistant Hypertension</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) global grow public health problem , frequency increase age . The major complication CKD involve lose renal function cardiovascular disease , result significant morbidity , mortality , cost . The main measure treatment CKD optimize drug therapy renal replacement therapy . Optimizing drug therapy , include vascular angiotensin-converting enzyme inhibitor , calcium antagonist , diuretic , beta adrenoceptor block agent , statin , platelet aggregation inhibitor , anticoagulant . However , situation treatment CKD satisfying . Sympathetic overactivity play key role development progression CKD . Sympathetic nerve activity increase patient stage CKD , associate cardiovascular event all-cause mortality . At time , hypertension proteinuria become important risk factor progression CKD . Recently , many clinical research verify Catheter-based renal sympathetic denervation safely use substantially reduce muscle whole-body sympathetic-nerve activity ( MSNA ) whole-body norepinephrine spillover . Simultaneously , mark reduction blood pressure , sleep apnea severity urine micro albumin level apparent , improvement glucose tolerance . Sympathetic activation , high norepinephrine level , hypertension , glucose tolerance abnormity , proteinuria obstructive sleep apnea recognize independent risk factor development progression CKD . So , design randomize parallel control clinical study demonstrate whether RSD slow progression CKD reduce rate all-cause mortality effectively securely .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject ≥ 18 ≤75 year age . 2 . A serum creatinine level 1.5 5.0 mg per deciliter ( 133 442 μmol per liter ) , creatinine clearance 20 70 ml per minute per 1.73 m2 , variation less 30 percent three month randomization . 3 . Persistent proteinuria ( defined urinary protein excretion 0.3 g per day three month evacuate urinary tract infection overt heart failure [ New York Heart Association class III IV ] ) . 4 . Resistant hypertension . 5 . Nondiabetic renal disease . 6 . Subject willing able comply protocol 7 . Subject expect remain available followup visit study center 8 . Subject Informed Consent . 1 . Current treatment corticosteroid , nonsteroidal antiinflammatory drug , immunosuppressive drug . 2 . Connectivetissue disease . 3 . Obstructive uropathy . 4 . Congestive heart failure ( New York Heart Association class III IV ) . 5 . Subject significant renovascular abnormality ( history prior renal artery intervention , include balloon angioplasty stenting ; double renal artery one side , distortion , extension ) , measure abdominal ultrasound renal angiogram . 6 . Subject history myocardial infarction , unstable angina , cerebrovascular accident alimentary tract hemorrhage previous 3 month . 7 . Subject sick sinus syndrome . 8 . Subject history allergy contrast medium ; psychiatric disorder ; drug alcohol abuse ; pregnancy . 9 . Enrolled concurrent study may confound result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Resistant hypertension</keyword>
	<keyword>All-cause mortality</keyword>
	<keyword>Renal function</keyword>
</DOC>